https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-31 / Mol. Ther. 2018 04;26(4):1008-1019
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-31 / Mol. Ther. 2018 04;26(4):1008-10192018-01-31 00:00:002019-02-15 09:23:16Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-09 / Cancer Sci. 2018 Feb;109(2):279-288
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-09 / Cancer Sci. 2018 Feb;109(2):279-2882018-01-09 00:00:002019-02-15 09:23:17Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-03 / Sci Transl Med 2018 01;10(422)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-03 / Sci Transl Med 2018 01;10(422)2018-01-03 00:00:002018-01-03 00:00:00Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-20 / Trends Immunol. 2018 03;39(3):209-221
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-20 / Trends Immunol. 2018 03;39(3):209-2212017-12-20 00:00:002019-02-15 09:23:08Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-19 / Eur Urol Focus 2018 04;4(3):442-454
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-19 / Eur Urol Focus 2018 04;4(3):442-4542017-10-19 00:00:002022-09-27 09:05:10Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-20 / Oncoscience 2017 Jul;4(7-8):67-692017-09-20 00:00:002019-02-15 08:36:14Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-19 / J. Biotechnol. 2017 Oct;260:91-972017-09-19 00:00:002017-09-19 00:00:00Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-2516
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-25162017-09-13 00:00:002017-09-13 00:00:00Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-08 / Front Oncol 2017;7:195
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-08 / Front Oncol 2017;7:1952017-09-08 00:00:002019-02-15 09:23:13Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-2352017-09-01 00:00:002019-02-15 08:51:59Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
